Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $9.7 million.

  • Biodesix's Accumulated Expenses rose 1364.43% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.7 million, marking a year-over-year increase of 1364.43%. This contributed to the annual value of $10.1 million for FY2024, which is 3053.18% up from last year.
  • According to the latest figures from Q3 2025, Biodesix's Accumulated Expenses is $9.7 million, which was up 1364.43% from $9.7 million recorded in Q2 2025.
  • Biodesix's 5-year Accumulated Expenses high stood at $10.1 million for Q4 2024, and its period low was $5.7 million during Q1 2023.
  • Moreover, its 5-year median value for Accumulated Expenses was $7.4 million (2025), whereas its average is $7.6 million.
  • As far as peak fluctuations go, Biodesix's Accumulated Expenses tumbled by 1499.59% in 2022, and later skyrocketed by 3759.58% in 2024.
  • Over the past 5 years, Biodesix's Accumulated Expenses (Quarter) stood at $7.7 million in 2021, then grew by 7.21% to $8.2 million in 2022, then decreased by 6.18% to $7.7 million in 2023, then soared by 30.53% to $10.1 million in 2024, then fell by 3.42% to $9.7 million in 2025.
  • Its last three reported values are $9.7 million in Q3 2025, $9.7 million for Q2 2025, and $7.4 million during Q1 2025.